MYOV

$26.98-$0.01 (-0.04%)prev close

Compare

Change+$4.80

Fair-value model

Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.

Years of analysisAssumption entries

Analyst estimates unavailable for this ticker.

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institutions

Sector

Biotechnology

P/S (TTM)

6.9

Earnings surprises

Beat consensus in 4 of the last 8 reported quarters

Reported	Est. EPS	Actual	Surprise
2023-01-26	$-0.47	$-0.59	-25.5%
2022-10-26	$-0.49	$-0.47	+4.1%
2022-07-27	$-0.32	$-0.22	+31.3%
2022-05-10	$-0.57	$-0.63	-10.5%
2022-01-26	$-0.61	$-0.68	-11.5%
2021-10-26	$-0.38	$-0.23	+39.5%
2021-07-28	$-0.34	$-0.67	-97.1%
2021-05-11	$-0.99	$-0.89	+10.1%

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
MYOVMyovant Sciences Ltd.	$26.98	-0.04%	$2.6B	—
BLUBELLUS Health Inc.	$14.74	+0.03%	$1.9B	—
CALTCalliditas Therapeutics AB (publ)	$40.00	-0.10%	$2.1B	—
DICEDICE Therapeutics, Inc.	$47.55	+0.06%	$2.3B	—
FUSNFusion Pharmaceuticals Inc.	$21.55	+0.14%

Myovant Sciences Ltd.

Myovant Sciences Ltd. is a biopharmaceutical company focused on innovating healthcare solutions for both women and men. Its flagship product is relugolix, an orally administered, once-daily small molecule that functions as a gonadotropin-releasing hormone (GnRH) receptor antagonist. This medication is indicated for conditions such as heavy menstrual bleeding caused by uterine fibroids, pain associated with endometriosis, and advanced prostate cancer. The company is also developing MVT-602, an oligopeptide kisspeptin agonist, currently in Phase II clinical trials for treating female infertility within assisted reproductive procedures. Myovant collaborates with Pfizer Inc. for the development and commercialization of relugolix across oncology and women's health sectors. Incorporated in 2016, initially as Roivant Endocrinology Ltd. before rebranding to Myovant Sciences Ltd. in May of that year, the firm is based in London, United Kingdom, and operates as a subsidiary of Sumitovant Biopharma Ltd.

myovant.com

Employees: 579
IPO / List date: Oct 27, 2016
HQ: GB

Held by traders on TradeandTell

No one on the platform currently holds MYOV.

Super investors & insiders

Institutions holding (13F)

No tracked institution reports a position in MYOV as of their last filing.

Insider activity (SEC Form 4)

No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded MYOV yet.

$MYOV chatter on StockTwits

Jake@Kingjake26May 15
$CADL Been part of several buyouts. I’m not sure what will happen here. Buyout or go on own but this is a multi billion dollar opportunity. I was part of big buyouts. $VRNA $MYOV CCXI. And a few others. Plus I own $CAPR with over 500% gain. Just a major opportunity My two two investments are CADL and CAPR
View on StockTwits ↗
Jake@Kingjake26May 9
@Zyntax @Adamchristlover not sure but I have been part of three buyouts. Ccxi, $VRNA and $MYOV . Also in another company they went 15x before selling. $NVCR . I truly believe we are way undervalued.
View on StockTwits ↗
Jake@Kingjake26Apr 29
@Whiskeyunderthebed I’m not perfect but I do have a decent track record. Buyouts in. $VRNA $CCXI. $MYOV and 500% gain and still holding some in CAPR. I have been wrong on a few ALDX and Iova. I announced I sold those two early. And I actually made a gain on aldx and lost some on Iova. @Rascal7777777 told me about CAPR. :) Really like $CADL My top holding right now.
View on StockTwits ↗
Quad@Quad_BullishFeb 16
$TGTX Fun fact: Right before Sumitomo announced it's original offer for $MYOV in 2022, short interest increased 10.83%. September 15, 2022 - 3,286,759 September 30, 2022 - 3,642,652 That's an increase of 355,893 shares, or 10.83%. Dumb shorts.
View on StockTwits ↗
Jake@Kingjake26Feb 11
@stu4 you may want to look in the mirror man. We see people like you all the time. Ilook at both sides and I like the risk reward. We had great phase 3 data. Yes it take time. People in general aren’t very patient patients will pay here based on the science. This is why most retail lose because they want instant gratification. It paid big time for me on other bio techs I held. For example $CCXI ,$MYOV $VRNA which all were bought out. Also holding $CAPR as well and made big gains. I’ve seen your post. I know how you work. You try to scare people out of their shares it’s not gonna work with me bro. I know what I have here and you’re not gonna steal it
View on StockTwits ↗
Jason@TAG01BullishDec 15
@OptimistJP I hope they random drop 12 month data with 85% survival on like a thursday at 4pm.. would like nothing more that to catch fockery shorts in position. but my strat holds. buy the dips and keep buying the dips till BO. worked on $CCXI, $PRVB, $MYOV, $VRNA, $CDTX.. looking forward to this withing 2 years.
View on StockTwits ↗
Quad@Quad_BullishDec 2
$TGTX Hope MW does well today. I keep telling myself... at least he's not Dave "Headwinds" Marek. Those of you that know, know. $MYOV
View on StockTwits ↗
Jason@TAG01BullishDec 1
@dcrown we would be giving away for 48.. imop. TAM is projecting 6B. thats just for Pancreatic. indications for liver and lung and others are also possible so this could be 10-15x from todsys numbers easy. load your position and wait for the manipulators to have their fill and reatail shares reduced to less than 5-7% then we will lift off. would be this time next year for early Sanofi offer or others. But most likely 2 quarters after approval and commercialization and likely 1 more funding round in mid 2028 unless they can a voucher and sell it, but thats my opinion from what I have learned from being in $CCXI, $PRVB, $MYOV, $VRNA, $CDTX.
View on StockTwits ↗
Jake@Kingjake26Nov 21
@gmania @torotoro222 this is a long term one. You’re not going to make money over night. Pick good quality management teams that don’t cut corners. CEO is doing everything right. I have had three buyouts. $CCXI ,$MYOV and $VRNA Great value here. I believe we will have a amazing year in 2026
View on StockTwits ↗
Jake@Kingjake26Nov 20
@PxD_GDX @drizz It sucks. I remember when they walked down $MYOV and $PRVB and both was finally bought out. People sold and they lost out. I believe we have a great platform. The CEO is doing thing right. The people complaining are the ones down right now or the people that can’t buy more and is down currently. Just need to have patience and remember why you started an investment here in the first place. $XBI
View on StockTwits ↗
Quad@Quad_Oct 24
$TGTX After $MYOV ... I said to myself, "Quad, go find the next Myovant." Well, here I am. Found it. The only thing that's missing is that the CEO's wife isn't checking out my LinkedIn page.
View on StockTwits ↗
Jake@Kingjake26Oct 22
@Burning_Cash Agreed. I have also been part of big buyouts as well. $VRNA $MYOV and $CCXI I believe we have a greets company here. We will see.
View on StockTwits ↗
Jake@Kingjake26Oct 6
@sck2 i seriously see this getting bought out and under the radar. I hope the shorts get what they deserve here just like my favors of $VRNA $CCXI $MYOV that was bought out. It was a blessing to be part of those companies
View on StockTwits ↗
Jason@TAG01BullishSep 30
@LolloTek yes buy hold sell at phese 3 or BO.. 1.5 year hold.. think this is the next $CCXI , $PRVB , $MYOV , $VRNA and Thomas Schall from CCXI is working there and he know the path to tak this to the finish line. CEO is rockstar on paper and presentation was good.. just sounds little young on phone. so far execution of company goals and funding have been flawless. Ithink currently we are just being fockery with by who ever took the public offering and they stole alot of people shares yeaterday..
View on StockTwits ↗
N@ngnolBullishAug 5
@Electric62 @Quad_ $myov put some hair in my chest
View on StockTwits ↗

Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.